{"id":"289777818743-24","name":"Boehringer Ingelheim","registrationDate":"2015-09-10T18:35:12.759+02:00","category":2,"subCategory":3,"legal":"GmbH","web":"http://www.boehringer-ingelheim.com","country":"Germany","headAddress":"Boehringer Ingelheim","headCity":"Ingelheim","headPostCode":"55216","headPhone":"(49)6 13 27 70","boss":"Hubertus von Baumbach","bossTitle":"Mr","bossPosition":"Chair of the Board of Managing Directors","membersCount":3,"membersFTE":"1.0","membership":"EFPIA (European Federation of Pharmaceutical Industries and Associations) &#xd;\nEBG (European Biosimilars Group)&#xd;\nIFAH - Animal Health Europe&#xd;\nEARA (European Animal Research Association)","memberOrga":"","goal":"The Boehringer Ingelheim group is one of the worldâ€™s 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 146 affiliates and more than 47,700 employees. Since it was founded in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing novel medications of high therapeutic value for human and veterinary medicine.","acronym":"","interests":"Budget, Business and Industry, Competition, Consumers, Customs, Economy, finance and the euro, Education and training, Employment and Social Affairs, Environment, International co-operation and development, Public Health, Research and innovation, Single market, Taxation, Trade","euInitiatives":"EU Health Policy&#xd;<br />EU Research Policy&#xd;<br />EU Trade Policy&#xd;<br />Innovative Medicines Initiative&#xd;<br />Health Technology Assessment&#xd;<br />Data Protection Regulation&#xd;<br />Medicine's Adaptive Pathways to Patients&#xd;<br />Veterinary policy and legislation&#xd;<br />EU Environment Policy","lastUp":"2019-07-04T16:50:01.244+02:00","customers":"","costAbsolu":"","costRange":"400000-499999","turnoverAbsolu":0,"turnoverRange":""}